What is the optimal cytotoxic regimen for advanced colorectal cancer?
Publication in refereed journal



摘要It is now well recognised that patients with metastatic colorectal cancer represent heterogeneous subgroups of patients with differing prognoses, because of differences in the number and sites of metastases, performance status, and the types of prior treatment. In fit patients with liver-only metastases in whom local ablative therapies may be rendered possible following downstaging of the metastases, multidrug systemic therapies achieving high tumour shrinkage rates may be the optimal choice. In contrast, patients with multiple sites of extrahepatic metastases or whose performance status is impaired, sequential single or two-drug regimens may be the more appropriate palliative approach, with the aim of extending progression-free survival. Recent studies have revealed that certain combinations of systemic therapies may result in overlapping toxicities or even worse clinical outcomes. A meta-analysis has also suggested that certain targeted therapies (monoclonal antibodies) may yield better clinical outcomes when combined with specific cytotoxic agents. Other special patient subgroups such as the elderly or those with impaired organ function deserve special consideration when selecting systemic therapies. This review summarises current data regarding optimal systemic therapy for different subgroups of patients with metastatic colorectal cancer. © 2011 Hong Kong College of Radiologists.
著者Ma B.
期刊名稱Hong Kong Journal of Radiology
期次4 SUPPL.
出版社Hong Kong Academy of Medicine Press
頁次31 - 36
關鍵詞Antineoplastic combined chemotherapy protocols, Colonic neoplasms, Liver neoplasms

上次更新時間 2020-04-09 於 02:42